Skip to main content

We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.

MASAC's latest set of recommendations cover the use and management of emicizumab, the latest products licensed to treat bleeding disorders, integrating the CDC's opioid prescribing guidelines into bleeding disorders care, and bleeding prophylaxis for patients undergoing gastrointestinal endoscopies. 

Dr. Valentino's COVID-19 Town Hall Webinar

On March 20th, NHF’s President and CEO answered your questions about how COVID-19 affects our community.

Health and Wellness Update from Dr. Valentino

Information and techniques you and your family can use to stay healthy during the COVID-19 pandemic.

NHF-HFA insurance question logo

Do you have questions regarding insurance coverage in light of the COVID-19 pandemic? We're here to help.

The halted trials were investigating concizumab prophylaxis treatment in hemophilia A and B patients regardless of inhibitor status.

NHF will update this page as more statements about product supply becomes available.

Subscribe to Our Newsletter

Fill in the fields below to receive our email newsletter.

* = Required Field